Publications by authors named "Yuju Ma"

Claim this Profile
A
Associations of motor and neuropsychiatric symptoms with comorbidities in prodromal Parkinson's disease.
Jia-Ru Chen, Yan Sun, Yu-Ju Ma, Lan Tan

Front Aging Neurosci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
Jan Lewis Brandes, David Kudrow, Paul P Yeung, Fumihiko Sakai, Ernesto Aycardi, Yuju Ma

Cephalalgia· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
Paul K Winner, Egilius L H Spierings, Paul P Yeung, Ernesto Aycardi, Tricia Blankenbiller, Yuju Ma

Headache· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fremanezumab for preventive treatment of migraine: Functional status on headache-free days.
Juliana VanderPluym, David W Dodick, Richard B Lipton, Yuju Ma, Pippa S Loupe, Marcelo E Bigal

Neurology· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Mary Bond, Kerri A Schoedel, Laura Rabinovich-Guilatt, Maciej Gasior, William Tracewell, Richard Malamut, Yuju Ma

Pain Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
David W Dodick, Stephen D Silberstein, Marcelo E Bigal, Paul P Yeung, Peter J Goadsby, Yuju Ma

JAMA· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fremanezumab for the Preventive Treatment of Chronic Migraine.
Stephen D Silberstein, David W Dodick, Marcelo E Bigal, Paul P Yeung, Peter J Goadsby, Yuju Ma

N Engl J Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
Martin E Hale, Thomas R Zimmerman, Yuju Ma, Richard Malamut

Pain Pract· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Mona Darwish, Mary Bond, Yuju Ma, William Tracewell, Philmore Robertson

Pain Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
Martin E Hale, Yuju Ma, Richard Malamut

J Opioid Manag· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients.
Dikla Gutman, Edward Hellriegel, Ernesto Aycardi, Marcelo E Bigal, Jeevan Kunta, Yuju Ma, Mark Pierce

Headache· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points.
Marcelo E Bigal, David W Dodick, Abouch V Krymchantowski, Juliana H VanderPluym, Stewart J Tepper, Yuju Ma

Neurology· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
Martin E Hale, Thomas R Zimmerman, Yuju Ma, Richard Malamut

J Opioid Manag· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Marcelo E Bigal, Lars Edvinsson, Alan M Rapoport, Richard B Lipton, Egilius L H Spierings, Yuju Ma

Lancet Neurol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Marcelo E Bigal, David W Dodick, Alan M Rapoport, Stephen D Silberstein, Yuju Ma, Lawrence C Newman

Lancet Neurol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.
Daniel M Paulson, Daniel T Kennedy, Roger A Donovick, Randall L Carpenter, Maryann Cherubini, Yuju Ma

J Pain· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis